Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong…
Sorrento Therapeutics, Inc. a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19. The publication details preclinical…
Read More...
Read More...